Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Treatment of tumor induced iron deficiency with ferric carboxymaltose (FCM, ferinject®)

Steinmetz, T., Tschechne, B., Selak, E., Kellner, T., Schröder, D., Marschner, N., Virgin, G., Kaldeweier, A., 2010.

Onkologie 33 (suppl 6)(P250), 74. doi:10.1159/000321409

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Onkologie
Ferinject-NIS
2010
Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuther, U., Busies, S., 2010.

J Clin Oncol 28(Sup. abstr e15086). doi: 10.1200/jco.2010.28.15_suppl.e15086

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
TNK
2010
Physicians underestimate the severity of fatigue, stomatitis, HFS and dysgeusia in mRCC-patients on systemic therapy: Interimanalysis of the Fatigue, Mucositis, Hand-Foot-Syndrome, and Dysgeusia in RCC study (FAMOUS).

Marschner, N., Münch, A., Lerchenmüller, C., Linz, B., Müller, L., 2010.

Onkologie 33 (suppl 6)(P203), 58. doi:10.1159/000321407

Abstract

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Onkologie
TNK
2010
Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Marschner, N., Münch, A., Blumenstengel, K., Sauer, U., Müller, L., 2010.

Ann Oncol, Abstract 949 21(suppl 8), viii298. doi:10.1093/annonc/mdq525

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
TNK
2010
Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten beim behandlungsbedürftigen metastasierten oder lokal fortgeschrittenen Nierenzellkarzinom.

Marschner, N., Müller, L., 2010.

Presented at the 29. Deutscher Krebskongress (DKK), Berlin.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DKK / Journal: -
TNK
2010
Klinische Tumorregister als Instrument der Versorgungsforschung: Das Netzwerk der niedergelassenen Hämatologen und Onkologen.

Marschner, N., Jänicke, M., 2010.

Remission, 3, 3–5.

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Remission
Registerübergreifend
2010
Die Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – das RCC-Register.

Legal, W., Münch, A., Müller, L., Blumenstengel, K., Lück, A., Hipper, A., 2010.

J Urol Urogynäkol 17(Sonderheft 3), 7.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: Bayrische Urologenvereinigung / Journal: Journal für Urologie und Urogynäkologie
TNK
2010
Treatment of patients with lymphatic B-cell neoplasia (TLN-Registry): A “Real Life” treatment overview in outpatient, office-based cancer centres in Germany.

Knauf, W., Abenhardt, W., Aldaoud, A., Nacak, T., 2010.

Onkologie 33 (suppl 6)(V366), 132. doi:10.1159/000321410

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Onkologie
TLN
2010
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.

Kieback, D.G., Harbeck, N., Bauer, W., Hadji, P., Weyer, G., Menschik, T., Hasenburg, A., 2010.

Gynecol. Oncol 119, 500–505. doi:10.1016/j.ygyno.2010.08.006

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Gynecologic Oncology
TEAM
2010
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.

Hadji, P., Asmar, L., van Nes, J.G.H., Menschik, T., Hasenburg, A., Kuck, J., Nortier, J.W.R., van de Velde, C.J.H., Jones, S.E., Ziller, M., 2010.

J Cancer Res Clin Oncol. doi:10.1007/s00432-010-0964-y

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Journal of Cancer Research and Clinical Oncology
TEAM
2010